1997.12 Shandong Provincial Key Laboratory of Natural Medicines
1999.11 Shandong Provincial Drug Preclinical Research Center
2001.12 Ministry of Health Key Laboratory of Biotechnology Drugs
2009.01 National Major New Drug Development - Shandong Major New Drug Development Platform - Pharmacology Evaluation Unit Technical Platform
2010.01 National Shandong Innovative Drug Incubation Base - Biopharmaceutical Preclinical Evaluation Technical Platform
2012.12 Shandong Provincial Drug Release Engineering Technology Research Center
2015.01 National Technology Transfer Demonstration Institution
2015.11 National Certified Drug Evaluation GLP Laboratory
2018.10 Shandong Provincial Innovation Public Service Platform - Innovative Drug Development and Evaluation Service Platform
2019.01 Shandong Provincial Collaborative Innovation Center for Key Technologies and Industrialization of Innovative Drug Development
2019.04 Shandong Provincial New Technology Pharmaceutical Engineering Laboratory
2023.04 National Key Laboratory for Advanced Drug Delivery Systems
Achievements Review:
1 Second Prize of National Science and Technology Progress Award
17 New Drug Certificates
2 Projects under the National "863" Program
5 Projects under the National Major Science and Technology Special Project for the Creation of Major New Drugs (including sub-projects)
3 Projects approved for funding exceeding tens of millions of yuan under the Shandong Province "Major Science and Technology Special Project for Independent Innovation"
Representative Achievements:
Tijiao Capsule (awarded the National Science and Technology Progress Second Prize) Transferred to Shandong New Era Pharmaceutical Co., Ltd. Launched in 2008, with sales exceeding 100 million yuan, and sales exceeding 1.2 billion yuan in the first three years after listing Currently, the company's annual sales exceed 2 billion yuan, with a market share of over 75%
Platinum-based series of anticancer drugs (the earliest in China)
Broad-spectrum first-line anticancer drugs
Cisplatin, Carboplatin, Oxaliplatin were all first launched in the market
Currently still the main products of Qilu Pharmaceutical, Dezhou Pharmaceutical, and Dalian
3. Ge Gen Su and Formulations (original research laboratory)
Transferred to Yantai Luyin Pharmaceutical Co., Ltd. (trade name Pulelin)
There are currently 218 approval numbers in the market, produced by 120 companies
The market size exceeds 100 billion
4. Injectable Esomeprazole Sodium (Market Transformation from Basic Research)
Developed jointly with Dezhou Deyao Pharmaceutical Co., Ltd.
Approved for market in 2019
Potential economic benefits exceed 7 billion yuan
